(Q30409023)

21 June 2017

1 reference

23 October 2022

Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience (English)

1 reference

21 June 2017

0 references

1 reference

1 reference

6

Regina Dutkowski

1 reference

21 June 2017

2

Craig R Rayner

1 reference

21 June 2017

James R Smith

1

1 reference

21 June 2017

Barbara Donner

series ordinal

3

1 reference

21 June 2017

Martina Wollenhaupt

series ordinal

4

1 reference

21 June 2017

Klaus Klumpp

series ordinal

5

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 November 2011

2 references

21 June 2017

23 October 2022

2 references

21 June 2017

23 October 2022

28

1 reference

21 June 2017

issue

11

1 reference

21 June 2017

page(s)

927-959

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Pharmacokinetics of oseltamivir in young and very elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Determination of appropriate dosing of influenza drugs in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir dosing for influenza infection in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The metabolism and transplacental transfer of oseltamivir in the ex vivo human model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir and breastfeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Population pharmacokinetics of oseltamivir when coadministered with probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Outcomes of adults hospitalised with severe influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Reducing the burden of influenza-associated complications with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Update on avian influenza A (H5N1) virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Human infection with highly pathogenic H5N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Human infection with highly pathogenic avian influenza virus (H5N1) in northern Vietnam, 2004-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir in human avian influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Viral loads and duration of viral shedding in adult patients hospitalized with influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Critically Ill patients with 2009 influenza A(H1N1) in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Hospitalization in two waves of pandemic influenza A(H1N1) in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Fatalities associated with the 2009 H1N1 influenza A virus in New York city

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Permissive secondary mutations enable the evolution of influenza oseltamivir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Suspected oseltamivir-induced bradycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The influence of oseltamivir treatment on the risk of stroke after influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Encephalopathy associated with influenza epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Encephalitis and encephalopathy associated with an influenza epidemic in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Safety and pharmacology of oseltamivir in clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Safety of oseltamivir in pregnancy: a review of preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Safety and pharmacokinetics of oseltamivir at standard and high dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Antiviral therapy for influenza : a clinical and economic comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Antiviral agents for influenza: a comparison of cost-effectiveness data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Mitigation of pandemic influenza: review of cost-effectiveness studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0072-7

Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons

21 January 2018

1 reference

12 December 2020

Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.

1 reference

12 December 2020

Influenza in patients with hematologic disease: an ounce of prevention is worth a pound of cure

1 reference

12 December 2020

Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009.

1 reference

12 December 2020

The emergence of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland, November-December, 2009.

1 reference

12 December 2020

Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases

1 reference

12 December 2020

Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.

1 reference

12 December 2020

Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

1 reference

12 December 2020

Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009

1 reference

12 December 2020

Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center

1 reference

12 December 2020

Update: influenza activity--United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine

1 reference

12 December 2020

Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis

1 reference

12 December 2020

Influenza virus susceptibility and resistance to oseltamivir.

1 reference

12 December 2020

Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season

1 reference

12 December 2020

Start of the influenza season 2008-9 in Europe - increasing influenza activity moving from West to East dominated by A(H3N2)

1 reference

12 December 2020

Neuraminidase inhibitors for preventing and treating influenza in children

1 reference

12 December 2020

Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.

1 reference

12 December 2020

Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010

1 reference

12 December 2020

10.1007/S12325-011-0072-7

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1037382305

0 references

PMC publication ID

7101998

0 references

1 reference